Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH

Medicine Matters oncology


He is part of the steering group for the European School of Oncology Working Party on the Access to Innovation in Cancer Treatment. He was faculty for the annual ECCO European CanCer Organisation meeting and ESMO-Barcelona - speaking on Innovation and Value based medicine.


Paul was part of the team that developed and presented evidence to the Oncology Advisory drugs Committee of the FDA for the first successfully approved US biosimilar.  He is faculty for the Continuing Medical Education programme of the European Association of Hospital Pharmacists for 2016, 2017 & 2018 and a Core Lecturer for the European School of Oncology.


He is part of the British Medical Journal “Round Table” group on Biosimilars as well as a faculty member for the DIA Regulators Meeting on Biosimilars. He has been an adviser on medicines and biosimilars policy to several national health systems – both in the EU and beyond.


Disclosure information

In the last 2 years, Paul Cornes has received travel costs to attend meetings and/or received speaker fees from Accord Healthcare; Astro; Biogen; the European Commission; the Global Academy of Health Sciences; GBM-Australia; Mylan, Napp; Pfizer/Hospira; Sandoz.